Adaptive Radiotherapy for Glioblastoma

(UNITED-4 Trial)

This trial tests a new method of delivering radiation therapy for glioblastoma, a type of brain cancer. The study explores whether "dose painting" with smaller treatment areas can better control the cancer compared to standard radiation therapy. Researchers aim to assess how this approach impacts patients' survival, quality of life, and any side effects. The trial suits individuals diagnosed with glioblastoma or a similar brain tumor who qualify for combined chemotherapy and radiation treatment. Participants should be able to undergo MRI scans and have had a biopsy or surgery within the past 12 weeks. As an unphased trial, this study allows patients to contribute to innovative research that could lead to new treatment options.

The trial protocol does not specify whether you need to stop taking your current medications. However, since the trial involves concurrent chemoradiotherapy with temozolomide, it's best to discuss your current medications with the study team.

Research has shown that adaptive radiation therapy (ART) for glioblastoma is generally safe and well-tolerated. Studies have linked ART to better survival rates and minimal side effects. One study found that precisely focusing the radiation on the tumor, known as dose-painting, can be done safely and consistently, even in challenging cases.

Adaptive radiotherapy for glioblastoma is unique because it uses a technique called "dose painting" with reduced radiation margins. Unlike standard treatments, which typically deliver a uniform radiation dose to the tumor, dose painting allows for the customized delivery of higher radiation doses to specific parts of the tumor that are more aggressive. This targeted approach aims to maximize the destruction of cancer cells while minimizing damage to healthy tissue. Researchers are excited about this method because it could potentially improve treatment precision and effectiveness, offering new hope for patients with this challenging type of brain cancer.

Research has shown that adaptive radiation therapy (ART) for glioblastoma can help patients live longer with fewer side effects. In this trial, participants will receive ART using a technique called dose painting, which targets higher radiation doses directly on the tumor with detailed imaging. Studies have found that ART does not increase the risk of cancer recurrence at the edges of the treated area. This method has been linked to better survival rates. Specifically, another study found that ART enhances the precision of radiation delivery while protecting healthy brain tissue. Overall, ART, including dose painting with smaller treatment areas, appears promising for effectively treating glioblastoma.¹³⁶⁷⁸